Midsized Biotech Alliance Steps Up Lobbying Push on Drug Pricing
The Midsized Biotech Alliance of America Inc. filed a lobbying disclosure report for the second quarter of 2026, disclosing spending of $230,000 on federal advocacy efforts. The filing on July 5 marks the organization's effort to shape policy on issues affecting smaller biotech firms navigating an increasingly complex regulatory environment.
Why It Matters
The Trump administration's Most Favored Nation drug pricing policy is designed to bring U.S. drug prices in line with what other developed nations pay and is projected to generate $529 billion in savings over 10 years. But the policy creates a stark choice for drug companies. Those that sign MFN agreements and submit onshoring plans face zero percent tariffs until January 20, 2029, while those that decline face tariffs as high as 100 percent. The Midsized Biotech Alliance responded to the tariff ultimatum, arguing that the policy risks undermining American biotech companies that drive the majority of new breakthroughs in cancer, rare diseases, and other life-threatening conditions.
The Lobbyists
LMH Strategic Solutions LLC served as the registrant lobbying firm for the second quarter filing. The lobbying team included Alanna Temme, the firm's founder, and Amy Efantis, listed as the lead, while Max Walter is director of government affairs and health policy.
Temme brings Capitol Hill experience from her time as legislative director to former Rep. Jon Porter in 2009, as well as prior roles on the House Financial Services Committee and House Education and the Workforce Committee. Efantis brings an extensive background with five consecutive congresses spanning almost seven years.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article